Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results
Allurion Technologies Inc. (NYSE:ALUR), a leader in innovative weight loss solutions, is set to resume patient treatments in France next month following the successful resumption of product shipments. This announcement comes on the heels of new clinical data presented at the SOFFCO.MM meeting in Saint-Etienne, France.
15 States with the Best Healthcare in the US
The study evaluated 1,962 French patients using Allurion Technologies Inc. (NYSE:ALUR)'s Program, which features a swallowable gastric balloon and AI-powered health coaching. Over just four months, participants achieved an average 12.2% reduction in total body weight. Notably, muscle mass as a percentage of body weight increased by 6.6%, and lean body mass rose by 6.0%. Fat mass and visceral fat index dropped by 11% and 12.2%, respectively. These results suggest significant improvements in metabolic health.
Dr. Thibaut Coste, a leading bariatric surgeon, highlighted the importance of losing weight while increasing muscle mass for sustainable, long-term health benefits. Dr. Shantanu Gaur, Allurion Technologies Inc. (NYSE:ALUR)’s Founder and CEO, expressed enthusiasm about returning to the French market, emphasizing the company’s commitment to metabolically healthy weight loss and the potential for continued success in France.
While we acknowledge the potential of ALUR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALUR and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.
Disclosure: None.
Content Original Link:
" target="_blank">
